Patent · US Active

Pharmaceutical compound capable of induce immune protective response against Dengue virus having the capsid protein of the Dengue virus

US7790173B2 · kind B2 · utility

2Cited by

1References

10Claims

0Family size

Assignee

CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA · CU

Inventors

Laura Lazo Vazquez · Boyeros, CU
Lisset Hermida Cruz · Boyeros, CU
Carlos Lopez Abarrategui · Boyeros, CU
Beatriz de la Caridad Sierra Vazquez · Boyeros, CU
Susana Vázquez Ramundo · Boyeros, CU
Iris Valdez Prado · Boyeros, CU
Gerardo Enrique Guillen Nieto · Boyeros, CU
María Guadalupe Guzmán Tirado · Boyeros, CU
Aida Zulueta Morales · Boyeros, CU

Key dates

Filing date	Sep 18, 2006
Grant date	Sep 7, 2010
Priority date	—
Expiry date	Sep 18, 2026

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention describes a pharmaceutical compound which has the capsid protein of Dengue virus and which is capable of inducing, in the receptor, a protective immune response before the viral challenge, without inducing the Ab-dependent enhancement phenomenon.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.